Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Thiogenesis Therapeutics Corp., a biotech firm specializing in developing treatments for unmet pediatric diseases, has inked a research agreement with a leading U.S. pediatric hospital to assess its lead compound, TTI-0102, for Leigh syndrome – a rare, life-threatening genetic disorder. TTI-0102 aims to combat mitochondrial oxidative stress in Leigh syndrome by increasing antioxidant levels, potentially improving the condition. The company is preparing for a Phase 2a clinical trial following an anticipated pre-IND meeting with the FDA.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
